Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Aspirin Administration From Early Pregnancy Versus Initiation After 11 Weeks of Gestation for Prevention of Pre-Eclampsia in Highrisk Pregnant Women: Study Protocol for Randomized Controlled Trial Publisher



Hantoushzadeh S1 ; Behzadian A2 ; Hasheminejad MM3 ; Hasheminejad F4 ; Helal Birjandi A5 ; Akbari M6 ; Ghaemi M7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Vali-E-Asr Reproductive Health Research Center, Family Health Research Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Perinatology, Vali-E-Asr Hospital, Imam Khomeini Hospital Complex, Tehran, Iran
  3. 3. Iran University of Medical Sciences, Tehran, Iran
  4. 4. Asklepios Psychiatry Lower Saxony GmbH, Asklepios Specialist Clinic, Gottingen, Germany
  5. 5. Hannover Medical School, Clinic for Urology, Hannover, Germany
  6. 6. Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medicine Sciences, Isfahan, Iran
  7. 7. Vali-E-Asr Hospital, Imam Khomeini Hospital Complex, Iran

Source: International Journal of Reproductive BioMedicine Published:2024


Abstract

Background: Pre-eclampsia (PE) is a multiorgan disorder that affects 2–5% of all pregnant women. Present recommendations for when to start aspirin in high-risk women are after 11 wk of gestation. Objective: We present a protocol to investigate the effectiveness of aspirin use from early pregnancy, which is a randomized controlled trial to assess whether prescribed low-dose aspirin from early pregnancy reduces the prevalence of early and late-onset PE. Additionally, to compare the effectiveness of aspirin administration before and after 11 wk in reducing the occurrence of PE? Materials and Methods: All pregnancies at risk of PE, according to demographic and midwifery history, who are referred to the Maternal-Fetal Clinic of Tehran University hospital, Tehran, Iran were invited to take part in the trial. The outcomes of pregnancy and newborns will be gathered and analyzed. The first registration for the pilot study was in January 2023, and the participants were recognized as high-risk for PE. In addition, enrollment in the main study will begin as of October 2023. © Hantoushzadeh et al.